Federal regulators could restrict some 7-OH products as early as Friday, Nov. 13, according to NPR. The report says the Drug Enforcement Administration plans to limit a narrower set of 7-OH and MGPI products, specifically those with higher concentrations of 7-OH or MGPI. HHS and the DEA say they are not targeting natural kratom.
NPR reports that 7-OH, or 7-hydroxymitragynine, is a psychoactive ingredient in kratom that appears to act more like an opioid in the brain than kratom leaf does. Products with concentrated 7-OH are sold in tablets, gummies, tonics and chocolate at smoke shops, liquor stores, gas stations and online.
NPR profiled a 38-year-old man identified only as Tyler, who said he used kratom to help stop using opioids for about a decade. He later began taking 7-OH tablets, which he said produced an opioid-like feeling. Nearly a year and a half later, he entered a rapid detox program in Michigan to manage withdrawal.
A report based on data from 53 U.S. poison control centers found that kratom-related calls rose about 1,200% between 2015 and 2025, according to NPR. The report counted 233 kratom-associated deaths during that period, and 79% of those deaths involved multiple substances. The report does not separate kratom from 7-OH products. Its lead author, Chris Holstege of the University of Virginia, is quoted as saying the authors "were a bit stunned" by the findings.
Advocates argue that kratom products have helped people avoid traditional opioids and manage pain and mood disorders. NPR also reports that the American Kratom Association sued the DEA in August over the earlier restriction.